CN114401948A - 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜 - Google Patents

用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜 Download PDF

Info

Publication number
CN114401948A
CN114401948A CN202080064509.6A CN202080064509A CN114401948A CN 114401948 A CN114401948 A CN 114401948A CN 202080064509 A CN202080064509 A CN 202080064509A CN 114401948 A CN114401948 A CN 114401948A
Authority
CN
China
Prior art keywords
methyl
thiazole
phenyl
sulfinyl
bromophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080064509.6A
Other languages
English (en)
Chinese (zh)
Inventor
G·吕贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Red Bull GmbH
Original Assignee
Red Bull GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Bull GmbH filed Critical Red Bull GmbH
Publication of CN114401948A publication Critical patent/CN114401948A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080064509.6A 2019-09-13 2020-09-10 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜 Pending CN114401948A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197359.3 2019-09-13
EP19197359.3A EP3792252A1 (en) 2019-09-13 2019-09-13 Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances.
PCT/EP2020/075338 WO2021048284A1 (en) 2019-09-13 2020-09-10 Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances

Publications (1)

Publication Number Publication Date
CN114401948A true CN114401948A (zh) 2022-04-26

Family

ID=67956609

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080064509.6A Pending CN114401948A (zh) 2019-09-13 2020-09-10 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜

Country Status (7)

Country Link
US (1) US12612374B2 (https=)
EP (1) EP3792252A1 (https=)
JP (1) JP2022548859A (https=)
KR (1) KR20220062376A (https=)
CN (1) CN114401948A (https=)
CA (1) CA3154003A1 (https=)
WO (1) WO2021048284A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917350A (zh) * 2022-06-21 2022-08-19 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348457A (zh) * 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
WO2016023997A1 (en) * 2014-08-13 2016-02-18 Red Bull Gmbh Heterocyclic compounds with working memory enhancing activity
CN107522693A (zh) * 2017-08-15 2017-12-29 田野 一种6‑元芳香环或杂芳香环化合物及其制备方法和应用
WO2019197670A1 (en) * 2018-04-12 2019-10-17 Red Bull Gmbh (s)-enantiomeric form of a heterocyclic compound having motivation improving and/or reference memory enhancing activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
JP4394451B2 (ja) 2002-01-04 2010-01-06 ニューロサーチ、アクティーゼルスカブ カリウムチャネルモジュレーター
EP1472214A2 (en) 2002-02-08 2004-11-03 SmithKline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US7314875B2 (en) 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348457A (zh) * 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
WO2016023997A1 (en) * 2014-08-13 2016-02-18 Red Bull Gmbh Heterocyclic compounds with working memory enhancing activity
CN107522693A (zh) * 2017-08-15 2017-12-29 田野 一种6‑元芳香环或杂芳香环化合物及其制备方法和应用
WO2019197670A1 (en) * 2018-04-12 2019-10-17 Red Bull Gmbh (s)-enantiomeric form of a heterocyclic compound having motivation improving and/or reference memory enhancing activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917350A (zh) * 2022-06-21 2022-08-19 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Also Published As

Publication number Publication date
US12612374B2 (en) 2026-04-28
EP3792252A1 (en) 2021-03-17
US20220324821A1 (en) 2022-10-13
JP2022548859A (ja) 2022-11-22
CA3154003A1 (en) 2021-03-18
WO2021048284A1 (en) 2021-03-18
KR20220062376A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
JP4316794B2 (ja) イソキノリン誘導体及び医薬
JP7187575B2 (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
JP2017537948A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
JP2024517678A (ja) ソルチリン活性の修飾物質
WO2015197006A1 (zh) 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN111372579B (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
CN114401948A (zh) 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜
CN111253412A (zh) α-倒捻子素衍生物及其应用
JP2005527518A (ja) 新規なカルコン（ｃｈａｌｃｏｎｅ）誘導体とその使用
US10221147B2 (en) Heterocyclic compounds with working memory enhancing activity
DK3186257T3 (en) Hitherto UNKNOWN CHROMONOXIME DERIVATIVE AND ITS USE AS AN ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
US20210380545A1 (en) (s)-enantiomeric form of a heterocyclic compound having motivation improving and/or reference memory enhancing activity
KR20250002429A (ko) 피라졸로피리미딘 화합물의 신규 용도
CN117550997A (zh) 一种lat1抑制剂及其制法和应用
CA2624383C (en) Salts of modulators of ppar and methods of treating metabolic disorders
WO2021259798A1 (en) ((((3-halophenyl)(phenyl)methyl)sulfinyl)methyl)thiophene compounds and diastereomeric forms thereof for use in improving cognitive functions
KR100636515B1 (ko) 신규 형태의 축합 피리다지논 화합물
ES2965684T3 (es) Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CA2838257A1 (en) [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
EP2985279B1 (en) Heterocyclic compounds with working memory enhancing activity
WO2025133307A1 (en) Heterocyclic modulators of the nlrp3 inflammasome pathway
JP2020186182A (ja) 標的蛋白質分解誘導化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20241106

Address after: CH-6341 Swiss Post Street Baltimore City No. 3

Applicant after: Red Bull GmbH

Country or region after: Switzerland

Address before: 1 Scher Avenue, Lake Fuk, Austria

Applicant before: Red Bull GmbH

Country or region before: Austria

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220426

WD01 Invention patent application deemed withdrawn after publication